Moody Aldrich Partners LLC Buys 5,236 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)

Moody Aldrich Partners LLC boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 3.8% in the fourth quarter, HoldingsChannel reports. The firm owned 144,366 shares of the company’s stock after acquiring an additional 5,236 shares during the period. Crinetics Pharmaceuticals makes up approximately 1.4% of Moody Aldrich Partners LLC’s holdings, making the stock its 16th largest holding. Moody Aldrich Partners LLC’s holdings in Crinetics Pharmaceuticals were worth $7,381,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in CRNX. SG Americas Securities LLC grew its position in Crinetics Pharmaceuticals by 4,084.6% in the 4th quarter. SG Americas Securities LLC now owns 542,446 shares of the company’s stock worth $27,735,000 after purchasing an additional 529,483 shares during the period. Franklin Resources Inc. grew its position in Crinetics Pharmaceuticals by 61.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,390,110 shares of the company’s stock worth $73,815,000 after purchasing an additional 528,688 shares during the period. FMR LLC grew its position in Crinetics Pharmaceuticals by 8.8% in the 3rd quarter. FMR LLC now owns 4,455,770 shares of the company’s stock worth $227,690,000 after purchasing an additional 358,975 shares during the period. Vestal Point Capital LP bought a new stake in Crinetics Pharmaceuticals in the 3rd quarter worth approximately $10,476,000. Finally, Geode Capital Management LLC grew its position in Crinetics Pharmaceuticals by 10.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company’s stock worth $94,458,000 after purchasing an additional 169,746 shares during the period. Institutional investors own 98.51% of the company’s stock.

Insiders Place Their Bets

In other Crinetics Pharmaceuticals news, COO Jeff E. Knight sold 501 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.52, for a total value of $28,316.52. Following the sale, the chief operating officer now owns 51,653 shares in the company, valued at $2,919,427.56. The trade was a 0.96 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 6.00% of the company’s stock.

Crinetics Pharmaceuticals Stock Performance

CRNX opened at $38.22 on Wednesday. Crinetics Pharmaceuticals, Inc. has a fifty-two week low of $35.51 and a fifty-two week high of $62.53. The firm’s fifty day moving average is $50.22 and its 200 day moving average is $52.56.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing the consensus estimate of ($0.91) by ($0.05). During the same period last year, the firm posted ($1.01) EPS. Equities analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.73 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently weighed in on CRNX. Citigroup lifted their price target on shares of Crinetics Pharmaceuticals from $70.00 to $74.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Jefferies Financial Group upgraded shares of Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Wednesday, January 22nd. JMP Securities reiterated a “market outperform” rating and set a $87.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. Finally, HC Wainwright reiterated a “buy” rating and set a $81.00 price target on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $72.64.

Crinetics Pharmaceuticals Company Profile

Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.